Article Information
History
- May 17, 2021.
Article Versions
- You are currently viewing Version 1 of this article (May 17, 2021 - 09:32).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Philipe Gobeil1,
- Stéphane Pillet1,
- Annie Séguin1,
- Iohann Boulay1,
- Asif Mahmood1,
- Donald C Vinh2,
- Nathalie Charland1,
- Philippe Boutet3,
- François Roman3,
- Robbert Van Der Most4,
- Maria de los Angeles Ceregido Perez3,
- Brian J Ward1,2,† and
- Nathalie Landry1,†,*
- 1Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 3V9
- 2Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, QC H4A 3J1
- 3GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, Belgium
- 4GlaxoSmithKline Biologicals SA (Vaccines), rue de l’Institut 89, 1330 Rixensart, Belgium
- ↵*Corresponding author: Nathalie Landry, 1020 Route de l’Église, Bureau 600, Québec, Qc, Canada, G1V 3V9; Tel. 418 658 9393; Fax. 418 658 6699; landryn{at}medicago.com
↵† These individuals are equally credited as senior authors.
Posted May 17, 2021.
Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older
